8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 25, 2015

 

 

Spark Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-36819   46-2654405

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

3737 Market Street

Suite 1300

Philadelphia, PA

   19104
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (855) 772-7589

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01 Other Events

Spark Therapeutics, Inc. (the “Company”) is filing the risk factors attached to this Current Report on Form 8-K to update and supersede the risk factors contained in its periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to the Securities Exchange Act of 1934, as amended, including those under the heading “Item 1A. Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 25, 2015 and its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, filed with the SEC on November 6, 2015.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
No.

   

Exhibit Description

99.1    Risk Factors

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SPARK THERAPEUTICS, INC.
Date: November 25, 2015     By:  

/s/ Joseph W. La Barge

     

Joseph W. La Barge

General Counsel

Exhibit Index

 

Exhibit 99.1    Risk Factors